A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.
The nicotinic acetylcholine receptor alpha1 (nAChRalpha1) was investigated as a potential fibrogenic molecule in the kidney, given reports that it may be an alternative urokinase (urokinase plasminogen activator; uPA) receptor in addition to the classical receptor uPAR. In a mouse obstructive uropathy model of chronic kidney disease, interstitial fibroblasts were identified as the primary cell type that bears nAChRalpha1 during fibrogenesis. Silencing of the nAChRalpha1 gene led to significantly fewer interstitial alphaSMA(+) myofibroblasts (2.8 times decreased), reduced interstitial cell proliferation (2.6 times decreased), better tubular cell preservation (E-cadherin 14 times increased), and reduced fibrosis severity (24% decrease in total collagen). The myofibroblast-inhibiting effect of nAChRalpha1 silencing in uPA-sufficient mice disappeared in uPA-null mice, suggesting that a uPA-dependent fibroblastic nAChRalpha1 pathway promotes renal fibrosis. To further establish this possible ligand-receptor relationship and to identify downstream signaling pathways, in vitro studies were performed using primary cultures of renal fibroblasts. (35)S-Labeled uPA bound to nAChRalpha1 with a K(d) of 1.6 x 10(-8) m, which was displaced by the specific nAChRalpha1 inhibitor d-tubocurarine in a dose-dependent manner. Pre-exposure of uPA to the fibroblasts inhibited [(3)H]nicotine binding. The uPA binding induced a cellular calcium influx and an inward membrane current that was entirely prevented by d-tubocurarine preincubation or nAChRalpha1 silencing. By mass spectrometry phosphoproteome analyses, uPA stimulation phosphorylated nAChRalpha1 and a complex of signaling proteins, including calcium-binding proteins, cytoskeletal proteins, and a nucleoprotein. This signaling pathway appears to regulate the expression of a group of genes that transform renal fibroblasts into more active myofibroblasts characterized by enhanced proliferation and contractility. This new fibrosis-promoting pathway may also be relevant to disorders that extend beyond chronic kidney disease.
Zhang
Guoqiang
G
Division of Nephrology, Immunology, Seattle Children's Hospital Research Institute, Seattle, Washington 98101, USA. guoqiang.zhang@seattlechildrens.org
Kernan
Kelly A
KA
Thomas
Alison
A
Collins
Sarah
S
Song
Yumei
Y
Li
Ling
L
Zhu
Weizhong
W
Leboeuf
Renee C
RC
Eddy
Allison A
AA
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000378:metabolism*; D005355:Fibrosis / Q000473:pathology*; D007668:Kidney / Q000473:pathology*; D007674:Kidney Diseases / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011485:Protein Binding; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015398:Signal Transduction; D014403:Tubocurarine / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D014568:Urokinase-Type Plasminogen Activator; D014403:Tubocurarine
Anal Biochem. 1967 May;19(2):249-55
6048697
Nat Cell Biol. 2006 May;8(5):485-91
16622418
J Neurosci. 1994 May;14(5 Pt 2):3271-9
8182471
Front Biosci. 2008 May 01;13:5462-78
18508599
Thromb Res. 2007;120(6):871-6
17331567
Respir Res. 2004 Dec 10;5:27
15588326
FEBS J. 2007 Aug;274(15):3799-845
17651090
J Vasc Res. 2006;43(5):437-46
16899994
Biol Chem. 2003 Feb;384(2):229-36
12675515
J Biol Chem. 2000 Jun 2;275(22):16450-8
10749881
Proc Natl Acad Sci U S A. 1988 Jul;85(13):4894-7
3164478
Kidney Int. 2008 Jul;74(1):62-9
18401335
Am J Physiol Renal Physiol. 2007 Jul;293(1):F12-9
17356128
J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34
16882693
J Biol Chem. 2006 Jun 2;281(22):15345-51
16554301
Nucleic Acids Res. 2001 Apr 1;29(7):1433-42
11266543
J Recept Signal Transduct Res. 1999 Nov;19(6):939-51
10533982
Kidney Int. 2000 Apr;57(4):1521-38
10760088
Scand J Clin Lab Invest. 1955;7(3):239-45
13298600
Drug News Perspect. 2008 Mar;21(2):107-16
18389102
Mol Biol Cell. 2006 Jan;17(1):367-78
16267271
FEBS Lett. 1994 Aug 1;349(2):163-8
8050560
Nature. 1994 Mar 31;368(6470):419-24
8133887
Hum Gene Ther. 1999 Jul 1;10(10):1735-7
10428218
J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204
16335592
J Physiol. 2003 Aug 15;551(Pt 1):155-68
12824448
J Infect Dis. 2005 Aug 1;192(3):429-37
15995956
Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65
16198274
Exp Eye Res. 2009 Aug;89(2):133-9
19285070
Med Hypotheses. 1997 Jul;49(1):57-9
9247909
FEBS Lett. 2003 Jul 31;548(1-3):113-8
12885417
Hypertension. 1997 Apr;29(4):1007-13
9095091
J Cell Biol. 1989 Feb;108(2):637-45
2465296
J Biol Chem. 2008 Mar 7;283(10):6312-20
18174170
J Am Soc Nephrol. 2003 May;14(5):1254-71
12707394
J Biol Chem. 1998 Dec 11;273(50):33267-72
9837898
Blood Coagul Fibrinolysis. 2004 Jul;15(5):383-91
15205586
Trends Immunol. 2004 Aug;25(8):450-5
15275645
Proc Natl Acad Sci U S A. 1986 Jan;83(2):498-502
3455784
Thromb Haemost. 1994 Jan;71(1):19-25
8165642
Adv Clin Chem. 2008;45:31-45
18429492
J Cell Biol. 1985 Jan;100(1):86-92
3880760
J Am Soc Nephrol. 2003 May;14(5):1234-53
12707393
J Am Soc Nephrol. 2004 Aug;15(8):2090-102
15284295
J Am Soc Nephrol. 2007 Mar;18(3):846-59
17267741
J Am Soc Nephrol. 2002 Feb;13(2):411-422
11805170
EMBO J. 1990 Mar;9(3):783-90
2311580
Invest Ophthalmol Vis Sci. 1993 Apr;34(5):1876-9
8473125
Kidney Int. 2005 Jun;67(6):2221-38
15882265
Biochem Pharmacol. 2001 Mar 15;61(6):733-40
11266659